RxDoctor Payments Data

Charles Prince, MD

Interventional Cardiology · Louisville, KYNPI 1861429615

Payments from drug & device makers

$1,431in general payments, 2019–2025

Across 89 payments — averaging $16.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$266
  • Johnson & Johnson$166
  • Pfizer$139
  • Abbott$121
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$84
  • AstraZeneca$69
  • plus $585 from 17 others

What the payments were for

  • Food & beverage$1,41599%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,431 in reported general payments places this provider in the 10th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$52,950
Medicare patients
254
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban185$163,233
EntrestoSacubitril/Valsartan144$148,894
FarxigaDapagliflozin Propanediol66$49,913
BrilintaTicagrelor53$36,952
Repatha SureclickEvolocumab28$17,044
XareltoRivaroxaban13$8,534
Metoprolol Succinate202$3,453
Prasugrel Hcl55$2,688
Amiodarone Hcl67$915
Potassium Chloride57$878
Bumetanide23$825
Atorvastatin Calcium116$818
Losartan Potassium96$687
Isosorbide Mononitrate ErIsosorbide Mononitrate78$665
SotalolSotalol Hcl32$661

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$139$163,233185 claims
NovartisEntresto$266$148,894144 claims
AstraZenecaFarxiga, Brilinta$69$86,865119 claims
Johnson & JohnsonXarelto$166$8,53413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →